We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Michael Grunwald

Michael R Grunwald MD

Chief, Leukemia Division, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina

Dr. Grunwald is Chief of the Leukemia Division and Associate Professor at Levine Cancer Institute of Atrium Health.  He cares for patients with acute and chronic leukemias, including myelodysplastic syndromes and myeloproliferative neoplasms.  He also cares for patients receiving cellular therapy, including blood and marrow transplants.  He is an active clinical investigator, leading trials for leukemia and transplant patients.  He participates in studies with the Blood and Marrow Transplant Clinical Trials Network and the Center for International Blood and Marrow Transplant Research.  He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplant and Cellular Therapy, American Medical Association, and American College of Physicians.

Disclosures

Dr. Grunwald has consulted for Abbvie, Alexion, Amgen, Ariad, Astellas, BMS/Celgene, Cardinal Health, Daiichi Sankyo, Merck, Pfizer, Premier, and Trovagene. Dr. Grunwald has received research funding from Amgen, Forma Therapeutics, Genentech/Roche, Incyte, Janssen, and Novartis.